Sawai Lays Out Ten Year Goals Including ¥400bn In Revenues
Plans Include Almost Doubling US Revenues From Upsher-Smith
Japan’s Sawai has laid out its mid- and long-term ambitions in a new company business plan, spanning both its local and overseas operations.
You may also be interested in...
Japan’s Nichi-Iko has reported operating profit that has plummeted by more than 95% in its latest financial year, as the firm suffered a forced shutdown of once of its Japanese plants and also recognized a substantial impairment linked to its US Sagent business.
Japan’s Towa Pharmaceutical has published its fifth mid-term business plan, alongside financial results for the 12 months ended 31 March 2021.
Sawai Pharmaceutical has major plans for its US business that include consolidating its manufacturing operations at a single site and bolstering its pipeline and portfolio, Sawai president Kenzo Sawai tells Generics Bulletin in an exclusive interview.